2003
DOI: 10.4321/s0212-71992003000200011
|View full text |Cite
|
Sign up to set email alerts
|

Tratamiento actual de la tuberculosis

Abstract: RESUMEN La tuberculosis (TB) es una enfermedad conocida desde la antigüedad y a pesar de los grandes avances en la medicina continúa siendo un problema grave de salud a nivel mundial. En este trabajo se realiza una revisión actualizada del tratamiento farmacológico de la tuberculosis teniendo en cuenta los principios generales de actuación de los medicamentos antituberculosos tanto de primera como de segunda línea. Se recogen los esquemas terapéuticos tanto de la enfermedad tuberculosa como de la tuberculosis … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
1
0
2

Year Published

2006
2006
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 13 publications
0
1
0
2
Order By: Relevance
“…According to the literature reviewed [ 17 ], mortality among nontreated PTB patients is 50% at five years after diagnosis. In the present study, in which all patients were diagnosed and received anti-TB treatment (according to current Mexican legislation, all patients diagnosed with PTB must be treated under DOTS), mortality was 23.6% at five years following diagnosis.…”
Section: Discussionmentioning
confidence: 99%
“…According to the literature reviewed [ 17 ], mortality among nontreated PTB patients is 50% at five years after diagnosis. In the present study, in which all patients were diagnosed and received anti-TB treatment (according to current Mexican legislation, all patients diagnosed with PTB must be treated under DOTS), mortality was 23.6% at five years following diagnosis.…”
Section: Discussionmentioning
confidence: 99%
“…44 40 García Ramos R., Lado Lado, F.L., Túnez Bastida, V., Pérez del Molino Bernal, M.L. y Cabarcos Ortiz de Barrón, A. (2003).…”
Section: Recerques I Assajosunclassified
“…Se ha de introducir un cuarto fármaco, etambutol (E), en poblaciones con tasas de resistencia primaria a H superiores al 4% (inmigrantes de Europa del Este, América Latina, África y Asia). Las dosis recomendadas se muestran en la tabla 2 12 . En cuanto a las cepas aisladas en la PI, la tasa de resistencias a los antituberculostáticos habituales utilizados en nuestro país es del 2,2% mientras que en diversos países que nos aportan inmigrantes alcanzaba entre el 5,6 y el 24% 13 .…”
Section: Tuberculosisunclassified